Home/Pipeline/MB310

MB310

Ulcerative Colitis

Phase 1bActive

Key Facts

Indication

Ulcerative Colitis

Phase

Phase 1b

Status

Active

Company

Microbiotica

About Microbiotica

Microbiotica is a UK-based, clinical-stage biotech translating microbiome science into defined live biotherapeutic medicines. Founded in 2016 as a spin-out from the Wellcome Sanger Institute, the company has raised £62M to date and is advancing two lead clinical programs: MB097 for enhancing immunotherapy in melanoma and MB310 for ulcerative colitis. Its core strength is a precision microbiome profiling platform that identifies bacterial signatures from clinical data to develop targeted therapies for specific patient populations.

View full company profile

Therapeutic Areas

Immuno-oncology Inflammatory Bowel Disease

Other Ulcerative Colitis Drugs

Drug	Company	Phase	Status
BB265	BiomeBank	Phase 1	Active
PALI-2108	Palisade Bio	Phase 2	Advancing towards initiation
ALTB-268	AltruBio	Phase IIa	Active
AIM-HI-UC	PathAI	Clinical Trials	Active
Patient Stratification in Ulcerative Colitis	Enable Medicine	Research	Active
Mesalazine (Lifecycle Management)	Dr. Falk Pharma	Approved/Phase 3	Active
AhR Agonist Program	Azora Therapeutics	Phase 1b	Active
R-3750	Virtici	Phase 1	Active
GPR35 Inhibitor	ThirtyFiveBio	Preclinical	Active
BT-600	Biora Therapeutics	Phase 1	Active
Asacol® (mesalazine)	Tillotts Pharma	Approved	Active
'1805	Revolo Biotherapeutics	Phase 2 (Planned)	Active